Target enzyme mutations cause resistance to cancer drugs
Author Information
Author(s): Uffe H. Olesen, Jakob G. Petersen, Antje Garten, Wieland Kiess, Jun Yoshino, Shin-Ichiro Imai, Mette K. Christensen, Peter Fristrup, Annemette V. Thougaard, Fredrik Björkling, Peter B. Jensen, Søren J. Nielsen, Maxwell Sehested
Primary Institution: Rigshospitalet, Copenhagen, Denmark
Hypothesis
Can mutations in the enzyme NAMPT lead to resistance against its inhibitors in cancer treatment?
Conclusion
Mutations in the NAMPT enzyme are primarily responsible for acquired resistance to NAMPT inhibitors in cancer cells.
Supporting Evidence
- 4 out of 5 resistant cell lines had mutations in NAMPT.
- Resistance was retained after 15 weeks without drug exposure.
- Mutations were located in the binding site or dimer interface of NAMPT.
Takeaway
Some cancer cells can become resistant to drugs that target a specific enzyme, and this resistance is often due to changes in the enzyme itself.
Methodology
The study involved developing resistant cell lines, sequencing the NAMPT gene, and conducting in vitro and in vivo experiments to assess drug resistance.
Limitations
The study did not explore all potential mechanisms of resistance and focused primarily on NAMPT mutations.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website